Therapeutic strategies for COVID-19: progress and lessons learned
G Li, R Hilgenfeld, R Whitley, E De Clercq - Nature Reviews Drug …, 2023 - nature.com
Abstract The coronavirus disease 2019 (COVID-19) pandemic has stimulated tremendous
efforts to develop therapeutic strategies that target severe acute respiratory syndrome …
efforts to develop therapeutic strategies that target severe acute respiratory syndrome …
An inhaled ACE2 decoy confers protection against SARS-CoV-2 infection in preclinical models
The Omicron variant continuously evolves under the humoral immune pressure exerted by
vaccination and severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection …
vaccination and severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection …
An IgM-like inhalable ACE2 fusion protein broadly neutralizes SARS-CoV-2 variants
J Liu, F Mao, J Chen, S Lu, Y Qi, Y Sun, L Fang… - Nature …, 2023 - nature.com
Many of the currently available COVID-19 vaccines and therapeutics are not effective
against newly emerged SARS-CoV-2 variants. Here, we developed the metallo-enzyme …
against newly emerged SARS-CoV-2 variants. Here, we developed the metallo-enzyme …
[HTML][HTML] Nanobodies to multiple spike variants and inhalation of nanobody-containing aerosols neutralize SARS-CoV-2 in cell culture and hamsters
The ongoing threat of COVID-19 has highlighted the need for effective prophylaxis and
convenient therapies, especially for outpatient settings. We have previously developed …
convenient therapies, especially for outpatient settings. We have previously developed …
Vectored immunoprophylaxis and treatment of SARS-CoV-2 infection in a preclinical model
T Tada, J Minnee, NR Landau - Proceedings of the …, 2023 - National Acad Sciences
Vectored immunoprophylaxis was first developed as a means of establishing engineered
immunity to HIV using an adenoassociated viral vector expressing a broadly neutralizing …
immunity to HIV using an adenoassociated viral vector expressing a broadly neutralizing …
[HTML][HTML] Decoy peptides effectively inhibit the binding of SARS-CoV-2 to ACE2 on oral epithelial cells
LK Loi, CC Yang, YC Lin, YF Su, YC Juan, YH Chen… - Heliyon, 2023 - cell.com
The entry of SARS-CoV-2 into host cells involves the interaction between the viral spike
protein and the human angiotensin-converting enzyme 2 (ACE2) receptor. Given that the …
protein and the human angiotensin-converting enzyme 2 (ACE2) receptor. Given that the …
SARS-CoV-2 evolution has increased resistance to monoclonal antibodies and first-generation COVID-19 vaccines: Is there a future therapeutic role for soluble ACE2 …
COVID-19 has caused calamitous health, economic and societal consequences. Although
several COVID-19 vaccines have received full authorization for use, global deployment has …
several COVID-19 vaccines have received full authorization for use, global deployment has …
Soluble Angiotensin-Converting Enzyme 2 Protein Improves Survival and Lowers Viral Titers in Lethal Mouse Model of Severe Acute Respiratory Syndrome …
C Cianfarini, L Hassler, J Wysocki, A Hassan… - Cells, 2024 - mdpi.com
Severe acute respiratory syndrome coronavirus type 2 (SARS-CoV-2) utilizes angiotensin-
converting enzyme 2 (ACE2) as its main receptor for cell entry. We bioengineered a soluble …
converting enzyme 2 (ACE2) as its main receptor for cell entry. We bioengineered a soluble …
Inhalation of ACE2-expressing lung exosomes provides prophylactic protection against SARS-CoV-2
Continued emergence of SARS-CoV-2 variants of concern that are capable of escaping
vaccine-induced immunity highlights the urgency of developing new COVID-19 therapeutics …
vaccine-induced immunity highlights the urgency of developing new COVID-19 therapeutics …
A computationally designed ACE2 decoy has broad efficacy against SARS-CoV-2 omicron variants and related viruses in vitro and in vivo
B Havranek, GW Lindsey, Y Higuchi, Y Itoh… - Communications …, 2023 - nature.com
Abstract SARS-CoV-2, especially B. 1.1. 529/omicron and its sublineages, continues to
mutate to evade monoclonal antibodies and antibodies elicited by vaccination. Affinity …
mutate to evade monoclonal antibodies and antibodies elicited by vaccination. Affinity …